FDA
approval
· 2022-02-25
FDA Approved: MYDAYIS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
Summary
FDA approved a supplemental application for MYDAYIS, a mixed amphetamine salts product for ADHD, submitted by Takeda Pharmaceuticals America, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for MYDAYIS (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE)